MESO

Interested in Mesoblast Limited? Here are five stocks we like better. RYONCIL generated $115 million in fiscal 2026 revenue, its first full year of commercial sales, while Mesoblast reduced its net loss by 44% to $57.5 million. The company ended the year with $103 million in cash and significantly lower second-half cash burn. Commercial momentum continued, with more than 50 treatment centers onboarded and insurance coverage reaching over 98% of U.S. lives. Mesoblast expects double-digit RYONCIL growth over the next 12 months and is conducting a 180-patient adult GVHD trial that could support label expansion. The pipeline advanced in Duchenne muscular dystrophy, chronic low back pain and heart failure: the FDA cleared a Phase III Duchenne trial, enrollment was completed in a 350-patient back-pain study, and the company is pursuing approval for REVASCOR in high-risk heart-failure patients. Mesoblast (NASDAQ:MESO) reported $115 million in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL, the company’s FDA-approved allogeneic mesenchymal stromal cell therapy for children with steroid-refractory acute graft-versus-host disease, or GVHD. Chief Executive Officer Silviu Itescu said fourth-quarter net revenue reached $36 million, while gross profit excluding amortization expenses totaled $110 million for the full year. The company described RYONCIL as the first and only FDA-approved mesenchymal stromal cell product in the U.S. → What Rising Delivery Forecasts Say About Rivian's Stock Prospects Chief Financial Officer Jim O’Brien said Mesoblast reduced its net loss after tax by 44% to $57.5 million. The company ended the fiscal year with $103 million in cash and reported net cash usage of $43.8 million for the year. Cash burn in the second half was $13.4 million, compared with $50 million in the corresponding prior-year period. Mesoblast said more than 50 treatment centers have been onboarded for RYONCIL, and insurance coverage now extends to more than 98% of U.S. lives. The company also received a J-code in October 2025, which Itescu said contributed to revenue growth. → NVIDIA Reveals $21 Billion SpaceX Stake: Signal of Confidence or Circular Financing? In real-world use, Itescu said RYONCIL has shown 84% early survival among treated children with acute GVHD. He said the company’s priorities over the next year include increasing adoption in the pediatric market, encouraging earlier use of the therapy, and expanding into adult GVHD. Mesoblast is enrolling a 180-patient randomized trial in adults with Grade 3 or 4 steroid-refractory acute GVHD. The study compares ruxolitinib alone with ruxolitinib plus RYONCIL. Itescu said the trial is enrolling across more than 40 U.S. sites and is expected to take about 18 months to complete. → Berkshire Boosts Its Bet: This AI Hyperscaler Is Now a Top-3 Holding The company expects an interim analysis in the fourth quarter of 2027 after approximately 100 patients, or 57% of the planned enrollment, have been enrolled. Itescu said either a successful interim analysis or a positive result from the full trial could support a supplemental biologics license application, or sBLA, for an adult label expansion. Discussing patients who have failed ruxolitinib, Itescu cited compassionate-use results showing 76% survival at day 100 among adolescents and adults treated with RYONCIL, compared with survival of roughly 20% to 30% in reports involving patients treated with other third-line agents after ruxolitinib failure. When asked about revenue expectations, Itescu did not provide formal guidance but said the company expects “double-digit growth” over the coming 12 months. He said management expects to have a clearer view of growth by the middle of the fiscal year. The FDA cleared Mesoblast’s investigational new drug application for a Phase III trial of RYONCIL in pediatric Duchenne muscular dystrophy. Itescu said the company is working with U.S. clinicians, patient groups and families to establish trial sites and begin the study. He said Mesoblast selected Duchenne muscular dystrophy because it believes its cell therapy could address inflammation early in the disease process, including in children as young as 3 or 4. The company expects the treatment could potentially be used alongside gene therapy approaches, according to Itescu. Mesoblast also completed treatment of all 350 patients in its pivotal Phase III trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. The company is following participants through 12 months and expects trial results in the second half of calendar 2027. If successful, Mesoblast plans to file a BLA, with a potential approval timeline in calendar 2028. Itescu said the pivotal study is designed to replicate an earlier Phase III trial in which a single injection produced pain reduction beginning at six months, peaking at 12 months and persisting through at least 36 months. The company said it is targeting patients with moderate-to-severe chronic low back pain who have not responded to medical therapies. Itescu said an outreach effort among pain specialists found that 85% were more likely to recommend rexlemestrocel-L if the prior clinical results were replicated in a commercial product. Mesoblast is also pursuing approval of REVASCOR, a rexlemestrocel-L program for advanced heart failure patients supported by left ventricular assist devices. Itescu said a prior randomized trial showed reductions in major gastrointestinal bleeding and hospitalizations related to right heart failure, along with improved survival among higher-risk ischemic patients. The company plans to seek full FDA approval in patients at risk of right heart failure and life-threatening bleeding. Itescu said a successful approval could potentially support later expansion into the larger Class II and III heart failure population. O’Brien said Mesoblast’s fiscal 2027 cash burn is expected to be lower than in fiscal 2026, supported by anticipated RYONCIL growth and cash receipts. He declined to provide a specific quarter in which the company expects to become cash-flow positive from operations. Mesoblast has a $125 million credit facility carrying an 8% interest rate, with no principal amortization for five years, according to O’Brien. He said the company intends to maintain financial flexibility while funding Phase III programs, manufacturing capabilities, regulatory filings and inventory needed to meet patient demand. Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective. The company's most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn's disease. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Mesoblast H2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2026. The webcast will begin at 6.30pm EDT, Wednesday, August 26; 8.30am AEST, Thursday, August 27, 2026. It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2026/ The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com. Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets. About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast Release authorized by the Chief Executive. For more information, please contact:

Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for Chronic Low Back Pain Activity Report for Quarter Ended June 30, 2026 (Appendix 4C) NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the fourth fiscal quarter ended June 30, 2026. “We are very pleased with the continued momentum in uptake of Ryoncil® in children with life-threatening steroid-refractory acute GvHD across major U.S. pediatric centers, positioning the treatment well for use next in adults with this life-threatening disease. We will continue to build on the strong first full year of Ryoncil® revenue to ensure our judicious use of capital facilitates achievement of key inflexion points for our blockbuster products, including potential FDA approvals.” said Mesoblast Chief Executive Dr. Silviu Itescu. FINANCIAL HIGHLIGHTS FOR THE FULL YEAR ENDED JUNE 30, 2026, THE FOURTH QUARTER AND THE SECOND HALF1 Ryoncil® net revenue for the fourth quarter was US$36 million. For the first full year post-FDA approval Ryoncil® net revenue was US$115 million, with US$66.5 million for the second half. Net operating cash spend for the full year was US$43.8 million, with operating cash spend of US$13.4 million for the second half. Mesoblast had US$103 million of cash at June 30, 2026, after having drawn down US$50 million from the existing five-year facility to extinguish all maturing debt obligations. OPERATIONAL HIGHLIGHTS FOR THE FOURTH QUARTER RYONCIL (remestemcel-L-rknd) The Company is executing on its strategy to extend its FDA-approved label for its flagship product Ryoncil® beyond children with steroid-refractory acute graft versus host disease (SR-aGvHD) to adults with SR-aGvHD, a market three times larger, and to both children and adults with other severe, life-threatening inflammatory conditions. The registration trial for label extension of Ryoncil® into adults with SR-aGvHD has commenced and is currently enrolling patients, with up to 40 sites across the U.S. expected to be activated this year representing approximately 60% of the ~8,500 annual U.S. allogeneic adult bone marrow transplant population. Mesoblast received Investigational New Drug (IND) clearance from U.S. Food and Drug Administration (FDA) to proceed directly to a registrational trial evaluating Ryoncil® in ambulatory children aged 5-9 years with Duchenne muscular dystrophy (DMD), which affects approximately 15,000 children in the U.S. REXLEMESTROCEL L Mesoblast achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease; these patients will be followed through the trial’s twelve-month primary endpoint to assess reduction in pain from baseline between rexlemestrocel-L and placebo-treated groups. Received a Biologics License Application (BLA) filing number from FDA and has requested a modular review of its BLA for rexlemestrocel-L in prevention of life-threatening gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device (LVAD). Other activities Held inaugural R&D day on April 8th in New York. A replay of the event is available here and presentation materials here. At the R&D day, Mesoblast unveiled next generation mesenchymal stromal cell (MSC) strategies including announcing the acquisition of an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform for precision-enhanced augmentation of therapeutic MSC products. This CAR technology provides Mesoblast with an immediate opportunity to generate products with even greater potency for ulcerative colitis or Crohn's disease. In addition, Mesoblast plans to use CAR-MSCs engineered to express CD19 on their surface to induce remission in Lupus Nephritis and other B cell autoimmune diseases where durable, effective and safe immunomodulation is highly desirable. CorporateFees to Non-Executive Directors were US$185,862, consulting payments to Non-Executive Directors were US$100,000, and salary payments to full-time Executive Directors were US$400,206, detailed in Item 6 of the Appendix 4C cash flow report for the quarter.2 A copy of the Appendix 4C – Quarterly Cash Flow Report for the fourth quarter FY2026 is available on the investor page of the company’s website www.mesoblast.com. About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com. Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets. About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast References / Footnotes The revenues included in this press release are based on management’s initial analysis of operations for the fourth quarter and full year ended June 30, 2026, and are subject to completion of Mesoblast’s financial closing procedures and audit. As required by ASX listing rule 4.7 and reported in Item 6 of the Appendix 4C, reported are the aggregated total payments to related parties being Executive Directors and Non-Executive Directors. Forward-Looking StatementsThis press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact:

Continued Growth Underpins First Full Year Net Revenue of US$115M NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net revenue of US$36 million for the quarter and US$115 million for the full year ended June 30, 2026. “We are very pleased with the strong uptake of Ryoncil® since launch, and with revenues that have already exceeded our initial projections,” said Mesoblast Chief Executive Dr. Silviu Itescu. Dr. Itescu added: “We anticipate continued revenue growth in the coming fiscal year in line with momentum we are seeing across major U.S. pediatric centers. Our capital position is strong, operational activities are well funded through revenue growth, and the new five-year facility has freed up our label extension and blockbuster products for strategic initiatives.” Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food and Drug Administration (FDA) for any indication and is the only FDA-approved product for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD).1 The results presented herein are based on management’s preliminary estimates and remain subject to completion of customary year end closing and audit procedures. About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com. Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets. About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast References / Footnotes Please see the full Prescribing Information at www.ryoncil.com Forward-Looking StatementsThis press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact:

Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third fiscal quarter ended March 31, 2026. “We’ve had a busy and exciting March quarter marked by a series of major achievements. Ryoncil® revenues are now approaching US$100 million since last year’s launch, we have substantially improved our net operating cash spend, our pivotal trial in inflammatory back pain has successfully achieved its patient recruitment target, and we have bolstered our long-term leadership in the field by acquiring genetically modified technology for precision-enhanced cell therapy products,” said Dr. Silviu Itescu, Mesoblast Chief Executive. FINANCIAL HIGHLIGHTS FOR QUARTER ENDED MARCH 31, 20261 Ryoncil® gross sales for the quarter were US$35.3 million, and net revenues were US$30.3 million.1 Strong sales in February and March offset holiday seasonality in January. Revenue generated during this first year of Ryoncil® launch approaches US$100 million. Net operating cash spend for the quarter was US$4.1 million. The reduction in net operating cash spend was driven by receipts of US$34.6 million and tight control of operating expenses. Mesoblast had US$122 million of cash at March 31, 2026. OPERATIONAL HIGHLIGHTS Achieved patient recruitment target in pivotal phase 3 trial of second-generation product rexlemestrocel-L for chronic low back pain (CLBP). Held inaugural R&D day on April 8th in New York. A replay of the event is available here and presentation materials here. At the R&D day Mesoblast highlighted its label extension strategy for Ryoncil® in adult and pediatric rare diseases, provided an update on near- and mid-term blockbuster opportunities in inflammatory back pain and heart failure, showcased leadership in allogeneic cell therapy innovation, and outlined commercial strategies for continued revenue growth. The trial for label extension of our flagship product Ryoncil® in adults with SR-aGvHD was cleared to begin by FDA, by data safety monitoring board (DSMB), and by central institutional review board (IRB) with first sites to be activated this quarter. FDA granted Investigational New Drug (IND) clearance to proceed directly to a registrational trial evaluating Ryoncil® in Duchenne’s muscular dystrophy (DMD), which affects approximately 15,000 children in the U.S. In addition, at the R&D day, Mesoblast unveiled next generation mesenchymal stromal cell (MSC) strategies including announcing the acquisition of an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform for precision-enhanced augmentation of therapeutic MSC products. This CAR technology provides Mesoblast with an immediate opportunity to generate products with even greater potency for ulcerative colitis or Crohn's disease. In addition, Mesoblast plans to use CAR-MSC engineered to express CD19 on their surface to induce remission in Lupus Nephritis and other B cell autoimmune diseases where durable, effective and safe immunomodulation is highly desirable. Other Fees to Non-Executive Directors were US$156,048, consulting payments to Non-Executive Directors were US$150,000, and salary payments to full-time Executive Directors were US$399,070, detailed in Item 6 of the Appendix 4C cash flow report for the quarter.2 A copy of the Appendix 4C – Quarterly Cash Flow Report for the third quarter FY2026 is available on the investor page of the company’s website www.mesoblast.com. About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com. Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets. About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast References / Footnotes Forward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact:

Strong growth in February/March following January seasonality Net revenue approaches US$100M since launch NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net sales were US$30.3 million for the quarter ended March 31, 2026.1 Strong sales in February and March offset holiday seasonality in January. Revenue generated during this first year of Ryoncil® launch approaches US$100 million. Ryoncil® revenue strengthens Mesoblast's balance sheet and supports label extension and late-stage blockbuster programs. Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food and Drug Administration (FDA) for any indication and is the only FDA-approved product for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD).2 “Revenue for Ryoncil® continues to be impressive,” said Mesoblast Chief Executive Dr. Silviu Itescu. “We will outline our growth strategy for Ryoncil® as well as our robust late-stage product pipeline at our inaugural R&D event this week.” Mesoblast will host its inaugural R&D Day on Wednesday, April 8, 2026, in New York City. The event will be webcast live from 8:00am to 11:00am EST and will include presentations from Mesoblast’s senior leadership team and from key opinion leaders. The webcast can be accessed via: https://webcast.openbriefing.com/msb-inv-2026/ A replay of the webcast will be available shortly after the conclusion of event on the Company’s website: www.mesoblast.com About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com. Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets. About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast References / Footnotes Forward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact:

Ryoncil launch drove strong early sales with $51.3 million total revenue in H1 (including $49 million net product revenue) and a 93% gross margin; management reiterated full-year Ryoncil net revenue guidance of $110–$120 million and the company ended December with $130 million in cash. Operating costs rose—R&D jumped to $46.1 million—and Mesoblast posted an operating loss of $40.2 million with H1 operating cash usage of $30.3 million, but it closed a $125 million non-dilutive credit facility ( $75 million drawn) to repay prior debt and has an additional $50 million tranche available. Commercial rollout shows momentum with 49 treatment centers onboarded, coverage across plans representing >280 million lives and a reimbursement code (J3402) in place; key clinical/regulatory milestones include adult GVHD pivotal sites starting after central IRB approval (anticipated March), a confirmatory Phase III low back pain trial completing enrollment in Mar/Apr with BLA/data expected in 2027, and a planned BLA filing next quarter for Revascor in LVAD patients as the company pursues full approval. Interested in Mesoblast Limited? Here are five stocks we like better. Mesoblast (NASDAQ:MESO) executives highlighted strong early commercial momentum for its cell therapy Ryoncil and outlined multiple regulatory and clinical milestones ahead during the company’s financial results call for the half year ended Dec. 31, 2025. Chief Executive Officer Silviu Itescu said fiscal 2026 to date has been marked by a “very successful product launch” following U.S. Food and Drug Administration approval of Ryoncil in December 2024. Ryoncil, which management described as the “first and only FDA-approved allogeneic mesenchymal stromal cell product,” launched in April 2025 and has shown quarter-on-quarter revenue growth. → SoundHound’s New Sales Assist Agent Put Voice AI Back in the Spotlight Chief Financial Officer James O’Brien reported total revenue of $51.3 million for the first half of fiscal 2026, including $49 million in net product revenue from Ryoncil. O’Brien said gross margin was 93%. On operating expenses, O’Brien said research and development expense was $46.1 million, compared with $5.1 million in the prior-year period. He noted the prior-year figure was “skewed” by a $23 million reversal of an inventory provision tied to Ryoncil’s approval; without that adjustment, he said prior-year R&D expense would have been about $18.1 million. Spending in the current period was attributed to adult graft-versus-host disease (GVHD) trials, the chronic low back pain program, the left ventricular assist device (LVAD) program, preparation for a biologics license application (BLA), and manufacturing work. → Diamondback Sees Resilient Demand Despite Cautious Guidance Sales and general administrative expense rose to $28.5 million from $18 million a year earlier, which O’Brien attributed to sales and marketing efforts supporting the launch. Mesoblast posted an operating loss of $40.2 million for the half, compared with $48 million in the prior-year period, which was also impacted by the prior-year inventory provision reversal. → Keurig Dr Pepper’s Split Plan Could Unlock Hidden Value O’Brien said operating cash flow usage was $30.3 million for the first half, and management expects cash usage to decline in the second half of fiscal 2026 based on projected revenue receipts and “disciplined cost control measures and efficiencies.” The company ended December with $130 million in cash, O’Brien said. O’Brien also detailed a financing transaction completed late in the period. On Dec. 30, 2025, Mesoblast entered into a $125 million “non-dilutive credit line facility.” The first $75 million tranche was drawn at closing and used to repay the prior senior secured loan in full, while the company also partially repaid a subordinated royalty facility that management expects will be fully repaid by mid-2026 from ongoing revenue. The remaining $50 million tranche is available at Mesoblast’s option through June 2026. O’Brien characterized the facility as a lower cost of capital that can be repaid at any time without early prepayment or make-whole fees and without exit fees. He also said the facility does not cover Mesoblast’s assets and has no restrictions on additional unsecured debt or licensing activities. Looking ahead, O’Brien said Mesoblast anticipates full-year fiscal 2026 Ryoncil net revenue of $110 million to $120 million. Management reiterated the guidance during the Q&A after an analyst asked for it to be repeated. Chief Commercial Officer Marcelo Santoro said the company is “extremely pleased” with launch performance and that Mesoblast has treated “numerous patients” since launch. He said the company is on track to achieve 20% market share by the end of year one in the market. Santoro reported operational metrics around rollout and access: 49 treatment centers onboarded to date Ryoncil listed on formulary at 30 of those centers 30 hospitals have opted to use Optum Frontier, the company’s specialty pharmacy partner Coverage in place across insurance plans representing over 280 million lives, across commercial and government payers Medicaid coverage in all states A specific reimbursement code, J3402, went into effect on Oct. 1 to support billing and reimbursement, along with published CMS rates He said major payers including Aetna, Cigna, UnitedHealthcare, Anthem, Humana, and Prime Therapeutics (covering Blue Cross plans) have issued favorable coverage policies and that these policies do not require step therapy. In response to an analyst question on the 20% share target, management said the goal is to reach 20% by the fourth quarter of the fiscal year, and Itescu said internal assumptions include a patient range of roughly 300 to 375 and a 40% peak share assumption over time, while noting the company believes the product “should be used by everyone.” Executives also said they are seeing both new centers adopt and “repeated use” at existing centers, alongside efforts focused on physician education and caregiver awareness. Beyond the pediatric indication, Itescu outlined plans to expand Ryoncil into adults. A pivotal study in adults with severe steroid-refractory GVHD is underway with partners at the NIH-funded Blood and Marrow Transplant Clinical Trials Network. Itescu said the protocol has been “locked down” after a recent FDA meeting, and the company expects site initiation and patient enrollment to begin after central IRB approval anticipated in March. Mesoblast also discussed its “second-generation platform,” rexlemestrocel-L, in chronic discogenic low back pain and chronic ischemic heart failure. Itescu said the company received positive FDA feedback on potential BLA filing for low back pain based on a clinically meaningful reduction in pain intensity at 12 months in a completed Phase III trial. He added that FDA confirmed 12-month pain reduction is an approvable endpoint, including under the current FDA administration, and noted the program has RMAT designation as a potential opioid-sparing therapy. A confirmatory Phase III trial is recruiting 300 patients across 40 U.S. sites, with enrollment expected to complete in March or April, and data readout and BLA filing expected in calendar 2027. For Revascor in end-stage heart failure patients supported by LVADs, Itescu reviewed results from two randomized controlled studies, including a 159-patient trial (LVAD study 2) and a supportive 30-patient trial (LVAD study 1). He said both trials showed Revascor reduced cumulative incidence of major bleeding events and related hospitalizations through six months. He also presented what he described as new data indicating reductions in major bleeding events and hospitalizations over 12 months, as well as effects on right heart failure hospitalizations and mortality risk. With orphan drug designation and ongoing work on chemistry, manufacturing, and controls, Itescu said Mesoblast is moving from an accelerated approval strategy to pursuing full approval for the LVAD indication and expects to file the BLA in the next quarter. In Q&A, management said it intends to seek a label for the overall LVAD patient population while providing FDA with data showing ischemic patients are at higher risk and may see greater benefit. Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective. The company's most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn's disease. The article "Mesoblast H1 Earnings Call Highlights" was originally published by MarketBeat.